当前位置: X-MOL 学术Lancet HIV › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
More evidence for dolutegravir as first-line ART for all.
The Lancet HIV ( IF 12.8 ) Pub Date : 2020-02-05 , DOI: 10.1016/s2352-3018(19)30414-x
Janne Estill 1 , Barbara Bertisch 2
Affiliation  

In The Lancet HIV, Andrew Phillips and colleagues present the results of a mathematical modelling study comparing first-line regimens in people initiating antiretroviral therapy (ART). They balance the risks and benefits of a dolutegravir-based regimen for all adults versus a dolutegravir-based regimen for all adults except women wanting (more) children, who will be treated with efavirenz.

中文翻译:

dolutegravir作为所有人的一线抗病毒药物的更多证据。

《柳叶刀艾滋病》中,安德鲁·菲利普斯(Andrew Phillips)及其同事介绍了数学建模研究的结果,该研究比较了开始抗逆转录病毒疗法(ART)的人们的一线治疗方案。它们平衡了针对所有成年人的基于dolutegravir的治疗方案与针对针对所有成年人的基于dolutegravir的治疗方案的风险和收益,除了想要(更多)孩子的妇女(将接受依非韦伦治疗)以外。
更新日期:2020-03-04
down
wechat
bug